Recruiting OBSERVATIONAL NCT07064330

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab. (NGF-GRACE)

Next Generation Flow Cytometry for Global Immunological Profile, Response And Toxicity Biomarker Signatures in Cutaneous Squamous Cell Carcinoma Under CEmiplimab Treatment.

Sponsor: Carlos III Health Institute

Conditions Cutaneous Squamous Cell Carcinoma (CSCC)

Interventions Cemiplimab

Updated 2 times since 2025 Last updated: Sep 3, 2025 Started: Jul 17, 2025 Primary completion: Jun 30, 2027 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07064330, this observational or N/A phase trial focuses on Cutaneous Squamous Cell Carcinoma (CSCC) and remains actively recruiting participants. Sponsored by Carlos III Health Institute, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Oct 2025 — Present [monthly]

Recruiting

Status: Active Not Recruiting → Recruiting
Aug 2025 — Oct 2025 [monthly]

Active Not Recruiting

First recorded

Jul 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Carlos III Health Institute
Instituto de Investigación Biomédica de Salamanca
Regeneron Pharmaceuticals
University of Salamanca

Data source: Instituto de Investigación Biomédica de Salamanca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salamanca, Spain